Brazilian Researchers Discover Molecule Showing Promise in Alzheimer’s Treatment
RIO DE JANEIRO, BRAZIL – A team of Brazilian scientists has identified a molecule, dubbed Hevina, that demonstrates the potential to revolutionize the treatment of Alzheimer’s disease. The breakthrough research, conducted by scientists from the University of São Paulo (USP), suggests a new therapeutic avenue focused on astrocytes – star-shaped brain cells – rather than the traditionally studied beta-amyloid plaques. Early tests indicate Hevina not only increases synaptic connections but also improves cognitive performance.
Alzheimer’s disease currently affects over 50 million peopel worldwide, a number projected to rise dramatically as the global population ages, according to the World Health Institution (WHO). While existing research has largely centered on addressing beta-amyloid buildup,this new discovery broadens the understanding of the disease’s progression and offers a possibly more effective target for future therapies. The findings represent a significant step toward slowing or even reversing the debilitating symptoms of Alzheimer’s, a condition with no current cure.
The research expands the focus beyond beta-amyloid plates, structures previously believed to be central to the disease’s progress. Brazilian scientists demonstrate that astrocytes play a direct role in the progression of Alzheimer’s and could become the focus of innovative treatments. Professor Danilo Bilches Medinas, from USP, noted the tests revealed both increased synaptic connections and improvements in cognitive task performance.
While Professor Medinas cautioned that Hevina is not yet ready for clinical submission as a medicine, he emphasized its potential as a promising pathway for future Alzheimer’s treatments. The discovery arrives at a critical juncture, as the need for new approaches to combat the disease grows increasingly urgent.
